Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation
Journal of Clinical Medicine · 20.02.2024 · 13 (5) · 1194
DOI: 10.3390/jcm13051194 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.02.2024. Verfasst von Robert Balk und 32 weiteren Autor:innen. Beteiligte Einrichtung: Rush Medical College and Rush University Medical Center, Chicago, IL 60612, USA. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immunexpress, Inc..
Themen: Sepsis
Abstract (Originalsprache)
(1)
Background
SeptiCyte RAPID is a molecular test for discriminating sepsis from non-infectious systemic inflammation, and for estimating sepsis probabilities. The objective of this study was the clinical validation of SeptiCyte RAPID, based on testing retrospectively banked and prospectively collected patient samples. (2)
Methods
The cartridge-based SeptiCyte RAPID test accepts a PAXgene blood RNA sample and provides sample-to-answer processing in ~1 h. The test output (SeptiScore, range 0–15) falls into four interpretation bands, with higher scores indicating higher probabilities of sepsis. Retrospective (N = 356) and prospective (N = 63) samples were tested from adult patients in ICU who either had the systemic inflammatory response syndrome (SIRS), or were suspected of having/diagnosed with sepsis. Patients were clinically evaluated by a panel of three expert physicians blinded to the SeptiCyte test results. Results were interpreted under either the Sepsis-2 or Sepsis-3 framework. (3)
Results
Under the Sepsis-2 framework, SeptiCyte RAPID performance for the combined retrospective and prospective cohorts had Areas Under the ROC Curve (AUCs) ranging from 0.82 to 0.85, a negative predictive value of 0.91 (sensitivity 0.94) for SeptiScore Band 1 (score range 0.1–5.0; lowest risk of sepsis), and a positive predictive value of 0.81 (specificity 0.90) for SeptiScore Band 4 (score range 7.4–15; highest risk of sepsis). Performance estimates for the prospective cohort ranged from AUC 0.86–0.95. For physician-adjudicated sepsis cases that were blood culture (+) or blood, urine culture (+)(+), 43/48 (90%) of SeptiCyte scores fell in Bands 3 or 4. In multivariable analysis with up to 14 additional clinical variables, SeptiScore was the most important variable for sepsis diagnosis. A comparable performance was obtained for the majority of patients reanalyzed under the Sepsis-3 definition, although a subgroup of 16 patients was identified that was called septic under Sepsis-2 but not under Sepsis-3. (4)
Conclusions
This study validates SeptiCyte RAPID for estimating sepsis probability, under both the Sepsis-2 and Sepsis-3 frameworks, for hospitalized patients on their first day of ICU admission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Rush Medical College and Rush University Medical Center, Chicago, IL 60612, USA.
- Grady Memorial Hospital and Emory University School of Medicine, Atlanta, GA 30322, USA.
- FirstHealth of the Carolinas, Pinehurst, NC 28374, USA.
- Intermountain Medical Center, Murray, UT 84107, USA.
- School of Medicine, University of Utah, Salt Lake City, UT 84132, USA.
- Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
ORCID-Profile: Greg S Martin, Neil R Aggarwal, Marcus J Schultz, Brendon P Scicluna, Thomas D Yager
Förderung
- Immunexpress, Inc.
Zitieren
APA
Balk, R., Esper, A. M., Martin, G. S., Miller, R. R., Lopansri, B. K., Burke, J. P., Levy, M., Opal, S., Rothman, R. E., D'Alessio, F. R., Sidhaye, V. K., Aggarwal, N. R., Greenberg, J. A., Yoder, M., Patel, G., Gilbert, E., Parada, J. P., Afshar, M., Kempker, J. A., …, & Brandon, R. B. (2024). Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation. Journal of Clinical Medicine, 13(5), 1194. https://doi.org/10.3390/jcm13051194
Vancouver
Balk R, Esper AM, Martin GS, Miller RR, Lopansri BK, Burke JP, et al. Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation. Journal of Clinical Medicine. 2024;13(5):1194. doi:10.3390/jcm13051194
BibTeX
@article{Balk2024,
author = {Balk, Robert and Esper, Annette M and Martin, Greg S and Miller, Russell R and Lopansri, Bert K and Burke, John P and Levy, Mitchell and Opal, Steven and Rothman, Richard E and D'Alessio, Franco R and Sidhaye, Venkataramana K and Aggarwal, Neil R and Greenberg, Jared A and Yoder, Mark and Patel, Gourang and Gilbert, Emily and Parada, Jorge P and Afshar, Majid and Kempker, Jordan A and van der Poll, Tom and Schultz, Marcus J and Scicluna, Brendon P and Klein Klouwenberg, Peter M C and Liebler, Janice and Blodget, Emily and Kumar, Santhi and Navalkar, Krupa and Yager, Thomas D and Sampson, Dayle and Kirk, James T and Cermelli, Silvia and Davis, Roy F and Brandon, Richard B},
title = {Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {5},
pages = {1194},
doi = {10.3390/jcm13051194}
}
EUVIMED